The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Venetoclax and magrolimab for treatment of AML and MDS
Jan Philipp Bewersdorf, MD, Yale School of Medicine, New Haven, CT, looks at the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax and justifies its use in the frontline setting, especially for patients with high-risk myelodysplastic syndrome (MDS) and high blast count. Currently, there are Phase I and II studies exploring its use when hypomethylating agents (HMAs) fail, and response to venetoclax has been seen. Magrolimab is an anti-CD47 monoclonal antibody with the potential in treating high-risk myelodysplastic syndrome (MDS). In combination with azacitidine, it is being investigated in a Phase III clinical trial. This interview took place during the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
